Clinical trial
A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult. Participants With NASH or Suspected NASH
NCT06104319 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult. Participants With NASH or Suspected NASH
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 22, 2024
- Completion date
- September 23, 2025
- Enrollment
- 61 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.